Evidence map›Paper›PMID 28630205›Full record

ArticleAntimicrobial agents and chemotherapy2017

Impact of

N Bablishvili, N Tukvadze, E Shashkina, B Mathema, N R Gandhi, H M Blumberg, R R Kempker

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

N BablishviliNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia nino_bablishvili@yahoo.com.
N TukvadzeNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
E ShashkinaPublic Health Research Institute, Rutgers University, Newark, New Jersey, USA.
B MathemaDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.
N R GandhiDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
H M BlumbergDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
R R KempkerDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Emory University · USNational Center for Tuberculosis and Lung Disease · GEColumbia University · USRutgers, The State University of New Jersey · US

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Role of antigen-specific T cell responses in the control of TBU19AI111211 · NIAID · EMORY UNIVERSITY · PI BLUMBERG, HENRY M, ERNST, JOEL D. · 2014 to 2020
$20.1M
Emory-Georgia TB Research Training ProgramD43TW007124 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Nestani Tukvadze · 2004 to 2026
$4.6M
Impact of HIV, Antiretroviral Therapy and TB Genotype on Survival in MDR TBR01AI087465 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2010 to 2014
$3.9M
Transmission of HIV-Associated XDR TB in Rural South AfricaR01AI089349 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2010 to 2014
$3.7M
Mentorship in Patient-Oriented Research in Tuberculosis, HIV and Global HealthK24AI114444 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2014 to 2023
$1.8M
Intra Cavitary Pharmacokinetics and Drug Resistance in Pulmonary TuberculosisK23AI103044 · NIAID · EMORY UNIVERSITY · PI KEMPKER, RUSSELL RYAN · 2013 to 2017
$910k
A Clinical Pharmacology Study of a Novel Drug Regimen for Pre XDR and XDR TuberculosisR21AI122001 · NIAID · EMORY UNIVERSITY · PI KEMPKER, RUSSELL RYAN · 2016 to 2017
$369k
FIC NIH HHS D43 TW007124NCATS NIH HHS UL1 TR000454NIAID NIH HHS K23 AI103044NIAID NIH HHS K24 AI114444NIAID NIH HHS R01 AI087465NIAID NIH HHS R01 AI089349NIAID NIH HHS R21 AI122001NIAID NIH HHS U19 AI111211
6 · The paper itself

Abstract

The country of Georgia has a high burden of multi- and extensively drug-resistant tuberculosis (XDR-TB). To evaluate whether mutations in

Indexed as

AcetyltransferasesAntitubercular AgentsBacterial ProteinsBase SequenceCapreomycinDNA GyraseDrug Resistance, Multiple, BacterialGeorgia (Republic)HumansKanamycinMycobacterium tuberculosisOfloxacinRetrospective StudiesSequence Analysis, DNATuberculosis, Multidrug-ResistantTuberculosis, PulmonaryAcetyltransferasesAntitubercular AgentsBacterial ProteinsCapreomycinDNA GyraseEis protein, Mycobacterium tuberculosisKanamycinOfloxacinDNA sequencingdrug resistanteisGeorgiagyrB

Identifiers

PMID28630205
PMCPMC5571295
OpenAlexW2704841676

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.